Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier
This invention relates generally to compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier.
1. A method for treating pain in a patient in need thereof which method comprises administering to said patient a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula I:
or a pharmaceutically acceptable salt thereof, wherein
R is hydrogen, alkyl, —C(O)-alkyl, or the group -L-S where L is a covalent bond or is a biocompatible, cleavable linking group and S is a dehydrating saccharide or oligosaccharide;
R 1 is hydrogen or the group -L-S where L is a covalent bond or is a biocompatible, cleavable linking group and S is a dehydrating saccharide or oligosaccharide; provided that at least one of R and R 1 is -L-S.
2. The method of claim 1 , wherein R is hydrogen or —C(O)alkyl and R 1 is -L-S.
3. The method of claim 1 , wherein R is -L-S and R 1 is hydrogen.
4. The method of claim 1 , wherein R and R 1 are -L-S.
5. The method of claim 1 , wherein R is hydrogen, mannopyranose, glucopyranose, glucopyranose-O—(CH 2 ) 9 C(O)—, ribofuranose, or ribopyranose.
6. The method of claim 1 , wherein R 1 is hydrogen, glucopyranose-O—(CH 2 ) 8 C(O)—, —C(O)O(CH 2 CH 2 O) 3 CH 3 or —CO 2 CH 2 CH 3 .
7. The method of claim 1 , wherein the pharmaceutical composition comprises a therapeutically acceptable amount of a compound of formula I and further comprises a pharmaceutically acceptable excipient.
8. The method of claim 7 , wherein R is hydrogen or —C(O)alkyl and R 1 is -L-S.
9. The method of claim 7 , wherein R is -L-S and R 1 is hydrogen.
10. The method of claim 7 , wherein both R and R 1 are -L-S.
11. A method for treating addiction in a patient in need thereof which method comprises administering to said patient a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula I:
or a pharmaceutically acceptable salt thereof wherein
R is hydrogen, alkyl, —C(O)-alkyl, or the group -L-S where L is a covalent bond or is a biocompatible, cleavable linking group and S is a dehydrating saccharide or oligosaccharide;
R 1 is hydrogen or the group -L-S where L is a covalent bond or is a biocompatible, cleavable linking group and S is a dehydrating saccharide or oligosaccharide; provided that at least one of R and R 1 is -L-S.
12. The method of claim 11 , wherein R is hydrogen or —C(O)alkyl and R 1 is -L-S.
13. The method of claim 11 , wherein R is -L-S and R 1 is hydrogen.
14. The method of claim 11 , wherein R and R 1 are -L-S.
15. The method of claim 11 , wherein R is hydrogen, mannopyranose, glucopyranose, glucopyranose-O—(CH 2 ) 9 C(O)—, ribofuranose, or ribopyranose.
16. The method of claim 11 , wherein R 1 is hydrogen, glucopyranose-O—(CH 2 ) 8 C(O)—, —C(O)O(CH 2 CH 2 O) 3 CH 3 or —CO 2 CH 2 CH 3 .
17. The method of claim 11 , wherein the pharmaceutical composition comprises a therapeutically acceptable amount of a compound of formula I and further comprises a pharmaceutically acceptable excipient.
18. The method of claim 17 , wherein R is hydrogen or —C(O)alkyl and R 1 is -L-S.
19. The method of claim 17 , wherein R is -L-S and R 1 is hydrogen.
20. The method of claim 17 , wherein both R and R 1 are -L-S.